Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Integrated Biomarker Study of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Resectable Metastatic Melanoma

Trial Profile

Pilot Integrated Biomarker Study of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Resectable Metastatic Melanoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pepinemab (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 04 Jun 2019 According to a Study design presented at the 55th ASCO meeting, as of 01 Feb 2019, 8 of 36 patients have been enrolled.
    • 04 Jun 2019 Study design was presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 15 May 2019 According to a Vaccinex media release, estimated primary completion date of this study is second half of 2020, and this study being conducted at the UCLA School of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top